Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE 2: CagriSema versus semaglutide, cagrilintide, and placebo in inadequately controlled type 2 diabetes on metformin with or without an SGLT2 inhibitor
MOH_2023-10-19_012875Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CagriSema, semaglutide and cagrilintide in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Oct 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2023-10-19_012875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-19_012875.